MAPT and Alzheimer disease: In an in vivo model for traumatic brain injury, Tg2576 mice demonstrated that daily administration of luteolin reduced AD pathology caused by the trauma, including tau hyperphosphorylation, GSK‐3β activity, and reduced Aβ deposition.[127] Furthermore, luteolin exhibited notable effects on SH‐SY5Y cells exposed to high zinc concentrations, an inducer of tau fibrillization in vitro.